Literature DB >> 9352578

Genetic analysis of CYP2C9 polymorphism in a Japanese population.

K Nasu1, T Kubota, T Ishizaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9352578     DOI： 10.1097/00008571-199710000-00011

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  49 in total

1.  The use of urine to clarify the genotype of a patient with toxic phenytoin concentrations who had undergone peripheral blood stem cell transplantation.

Authors:  Noritaka Ariyoshi; Katsuhiro Sho-no; Miki Nishimura; Michihiro Ito; Hiroyoshi Nakamura; Takayoshi Asai; Yasushi Saitoh; Takashi Ishizaki; Mitsukazu Kitada
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

3.  A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors:  Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 4.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese.

Authors:  Chen-Hui Luo; An Wang; Rong-Hua Zhu; Wei-Xia Zhang; Wei Mo; Bang-Ning Yu; Guo-Lin Chen; Dong-Sheng Ou-Yang; Xiao-Hong Duan; A M Abd El-Aty; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

6.  Allele and genotype frequencies of CYP2C9 in a Korean population.

Authors:  Jung-Woo Bae; Hyun-Kyung Kim; Ji-Hong Kim; Sang-In Yang; Mi-Jeong Kim; Choon-Gon Jang; Young-Seo Park; Seok-Yong Lee
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

7.  The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Authors:  Ya-Huei Liou; Chien-Ting Lin; Ying-Jye Wu; Lawrence Shih-Hsin Wu
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

8.  Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.

Authors:  Seitaro Terakura; Makoto Onizuka; Mariko Fukumoto; Yachiyo Kuwatsuka; Akio Kohno; Yukiyasu Ozawa; Koichi Miyamura; Yuichiro Inagaki; Masashi Sawa; Yoshiko Atsuta; Ritsuro Suzuki; Tomoki Naoe; Yoshihisa Morishita; Makoto Murata
Journal:  Int J Hematol       Date:  2019-09-25       Impact factor: 2.490

9.  CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Authors:  Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

10.  Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.

Authors:  Yu Cheng; Guo Wang; Wei Zhang; Lan Fan; Yao Chen; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2012-07-28       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.